Fasting is not routinely required for determination of a lipid profile: Clinical and Laboratory implications including flagging at desirable concentration cutpoints-A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

Clinical Chemistry

Volumn 62, Issue 7, 2016, Pages 930-946

  Nordestgaard, Børge G ^a   Langsted, Anne ^a   Mora, Samia ^b   Kolovou, Genovefa ^c   Baum, Hannsjörg ^d   Bruckert, Eric ^e   Watts, Gerald F ^f   Sypniewska, Grazyna ^g   Wiklund, Olov ^h   Borén, Jan ^h   Chapman, M John ^e   Cobbaert, Christa ⁱ   Descamps, Olivier S ^j   Von Eckardstein, Arnold ^k   Kamstrup, Pia R ^a   Pulkki, Kari ^l   Kronenberg, Florian ^m   Remaley, Alan T ⁿ   Rifai, Nader ^o   Ros, Emilio ^p,q   Langlois, Michel ^r,s   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

^d Regionale Kliniken Holding RKH GmbH   (Germany)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Hospital de Jolimont   (Belgium)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l UNIVERSITY OF EASTERN FINLAND   (Finland)

^m INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁿ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^o HARVARD UNIVERSITY   (United States)

^p HOSPITAL CLÍNIC   (Spain)

^q Instituto de Salud Carlos III   (Spain)

^r General Hospital St Jan   (Belgium)

^s GHENT UNIVERSITY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DENMARK; DIET RESTRICTION; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD INTAKE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PANCREATITIS; PREDICTION; ATHEROSCLEROSIS; BLOOD; CLINICAL CHEMISTRY; CONSENSUS; CONSENSUS DEVELOPMENT; EUROPE; LABORATORY TECHNIQUE; STANDARDS;

ATHEROSCLEROSIS; CHEMISTRY, CLINICAL; CLINICAL LABORATORY TECHNIQUES; CONSENSUS; EUROPE; FASTING; HUMANS; LIPIDS; SOCIETIES, MEDICAL;

EID: 84976520301     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.258897     Document Type: Article

References (48)

1. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Philadelphia: Elsevier Saunders; 2006, p. 903-982.
2. Simundic AM, Cornes M, Grankvist K, Lippi G, Nybo M. Standardization of collection requirements for fasting samples: For the Working Group on Preanalytical Phase (WG-PA) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chim Acta 2014;432: 33-7.
3. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: Influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118: 2047-56.
4. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118: 993-1001.
5. Watts GF, Cohn JS. Whither the lipid profile: Feast, famine, or no free lunch? Clin Chem 2011;57: 363-5.
6. Gaziano JM. Should we fast before we measure our lipids? Arch Intern Med 2012;172: 1705-6.
7. Khera AV, Mora S. Fasting for lipid testing: Is it worth the trouble? Arch Intern Med 2012;172: 1710-2.
8. Nordestgaard BG, Hilsted L, Stender S. [Plasma lipids in non-fasting patients and signal values of laboratory results.] [in Danish] Ugeskr Laeger 2009;171: 1093.
9. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 2011;57: 482-9.
10. NICE clinical guideline CG181. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. https://www.nice.org.uk/guidance/cg181/evidence/lipidmodification-updatefull- guideline-243786637 (Accessed October 2015).
11. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31: 2844-53.
12. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011;32: 1345-61.
13. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-818.
14. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011;123: 2292-333.
15. Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33: 1635-701.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
17. Tanno K, Okamura T, Ohsawa M, Onoda T, Itai K, Sakata K, et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010;411: 1774-80.
18. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009;55: 888-94.
19. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61: 427-36.
20. Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both lowgrade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013;128: 1298-309.
21. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384: 626-35.
22. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9.
23. Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: A significant component of serum cholesterol. Clin Chim Acta 2011;412: 1783-7.
24. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2: 655-66.
25. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol 2014;63: 2889-934.
26. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988;34: 2456-9.
27. Mihas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: A metaanalysis. Curr Vasc Pharmacol 2011;9: 271-80.
28. Klop B, Cohn JS, van Oostrom AJ, van Wijk JP, Birnie E, Castro CM. Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta 2011;412: 2183-9.
29. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: A cross-sectional study. Arch Intern Med 2012;172: 1707-10.
30. Steiner MJ, Skinner AC, Perrin EM. Fasting might not be necessary before lipid screening: A nationally representative cross-sectional study. Pediatrics 2011;128: 463-70.
31. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg- Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298: 299-308.
32. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating lowdensity lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013;310: 2061-8.
33. Lund SS, Jensen T. Using nonfasting lipids: Hemodilution or convenience? Clin Chem 2011;57: 1336-8.
34. Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014; 234: 95-101.
35. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007;115: 450-8.
36. Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302: 1993-2000.
37. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on longterm mortality: Insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014;130: 546-53.
38. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300: 2142-52.
39. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298: 309-16.
40. White KT, Moorthy MV, Akinkuolie AO, Demler O, Ridker PM, Cook NR, Mora S. Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem 2015;61: 1156-63.
41. Langsted A, Nordestgaard BG. Nonfasting lipid profiles: The way of the future. Clin Chem 2015;61: 1123-5.
42. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An expert panel statement. Curr Vasc Pharmacol 2011;9: 258-270.
43. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34: 3478-90.
44. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management: A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35: 2146-57.
45. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36: 2425-37.
46. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368: 503-12.
47. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63: 470-7.
48. Jessen RH, Dass CJ, Eckfeldt JH. Do enzymatic analyses of serum triglycerides really need blanking for free glycerol? Clin Chem 1990;36: 1372-5.